Isatuximab with carfilzomib, lenalidomide, and dexamethasone for treating high-risk, newly diagnosed multiple myeloma: A plain language summary
This Plain Language Summary of publication article (PLSP) from Future Oncology covers the GMMG-CONCEPT study, which assessed the safety of a drug combination—isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd)—for treating high-risk, newly diagnosed multiple myeloma. The study included both transplant-eligible and non-eligible participants.
Visit the site using this link to read the article.
This PLSP is based on an article called ‘Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Newly Diagnosed Multiple Myeloma’ and was published in the Journal of Clinical Oncology.
Visit ASCO Publications using the link to read the original article.